ALLO

Allogene Therapeutics Inc

$2.10

0.14 (6.31%) Today

0.02 (0.96%) After-hours

— up— down

Compare ALLO

Market Cap

$766M+84.1%

Revenue (TTM)

Net Income (TTM)

$-299,693,745

EPS (TTM)

-0.87

Shares Out

345.15M

Open

$2.24

Previous Close

$2.22

Day Range

$2.05 – $2.25

52-Week Range

$0.98 – $4.46

Beta

0.46

Earnings Date

Aug 11, 2026

Volume

17.95M

Avg Volume

9.21M

Analyst Rating

Buy

Exchange

NASDAQ NMS - GLOBAL MARKET

About ALLO

Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.